Spero Therapeutics, Inc.
sperotherapeutics.comWhat Do They Do?
Develops treatments for rare diseases and diseases with high unmet need, including an oral antibiotic for adults with complicated urinary tract infections.
10-K for FY2025, filed Mar 26, 2026
How Do They Make Money?
Collaboration revenue comes from licenses: partners pay upfront and milestone amounts, with royalties tied to product sales; the company also receives grant revenue.
10-K for FY2025, filed Mar 26, 2026The Company has entered into licensing agreements that are evaluated under Accounting Standards Codification, Topic 606 (“Topic 606”)…View ↗
In September 2022, we entered into the GSK License Agreement, for the development, manufacturing and commercialization of tebipenem HBr.…View ↗
In addition to the milestones described above, GSK is obligated to pay royalties to us on annual net sales of GSK Licensed Products in the…View ↗
-
10-K for FY2025, filed Mar 26, 2026
FY2025 revenue by product or service ↗
$66.8M
-
10-K for FY2025, filed Mar 26, 2026
$66.8M ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Grant Revenue
|
11% |
Grant Revenue, FY2025
$7.2M Sources
|
|
|
Collaboration revenue - related party
Licensed
10-K for FY2025, filed Mar 26, 2026 |
70% |
Collaboration revenue - related party, FY2025
$47M Sources
|
Licensed |
|
Collaboration revenue
Licensed
10-K for FY2025, filed Mar 26, 2026 |
19% |
Collaboration revenue, FY2025
$12.6M Sources
|
Licensed |
Who Are Their Customers?
Drug-development partners license product-candidate rights directly; GSK holds rights to develop and commercialize tebipenem in most territories, while Meiji retains certain Asian territories.
10-K for FY2025, filed Mar 26, 2026
Do Revenues Turn Into Profits?
Yes. It kept 13 cents of every revenue dollar as net income in FY2025.
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 12, 2026
−$9.6MView ↗
- ▲ +462% (Loss)
- vs −$1.7M in Q2 FY2025
-
Jul 14, 2026
Licensed SP001 rights for development and commercialization
Spero gained an exclusive license to develop, research, manufacture, and commercialize SP001 and related antibodies in the Licensed Territory.
Sources
8-K, filed Jul 14, 2026
On July 8, 2026, Spero Therapeutics, Inc. (the “Company”) entered into a license agreement (the “Innovent Agreement”) with Innovent…View ↗
-
Jun 22, 2026
FDA approved Utebzi for adults with complicated urinary tract infections
GSK holds commercialization rights in the U.S. and Europe; the product was expected to reach U.S. patients by the end of 2026.
Sources
8-K, filed Jun 22, 2026
On June 17, 2026, the Company issued a press release announcing that the FDA has granted approval for Utebzi (tebipenem pivoxil), an oral…View ↗
Growing. Revenue grew 3.7x in 4 years, from $18.3M in FY2021 to $66.8M in FY2025, about 38% a year.
Loading...
